Search Clinical Trials
Our Blood and Marrow Transplant Program is recognized as a leader in the field of blood and marrow transplant and patients are referred to us because of both our clinical excellence and advanced treatment protocols. Our objective is to have research trials available for most clinical situations to meet the needs of our patients. Our record shows that we are committed to reduce transplant toxicities and improve patient outcomes.
Search our database for a listing of clinical trials available at Taussig Cancer Institute.
Search Clinical Trials
The Blood & Marrow Transplant Clinical Trials Network
The Blood and Marrow Transplant Program collaborates with the BMT Clinical Trials Network (BMT CTN). BMT CTN was established because of a critical need for multi-institutional clinical trials focused directly on improving survival for patients undergoing hematopoietic cell transplantation (HCT).
Since 2001, the BMT CTN has opened more than 27 multi-institutional phase II and III trials, involved more than 100 transplant centers, and enrolled thousands of patients.
Although the Blood and Marrow Transplant Program offers state-of-the art autologous and allogeneic transplants to treat cancer, we do so in humble knowledge that we do not cure everybody. Our failures drive our ambition to improve our results and we do that with a robust research program. Our scientists, research nurses, data managers, and biostatisticians collaborate on studies that both reflect on what we have learned from our accumulated experience (retrospective research) to studies that test new ideas derived from that experience (prospective research).
Each year, we embark on new Blood and Marrow Transplant research protocols organized either by our own program, pharmaceutical companies, or cooperative groups like the Blood and Marrow Transplant Clinical Trial Network. Our work has historically focused more on autologous blood and marrow transplants but we are actively engaged now in prospective studies of allogeneic transplants. We have a special interest in studies designed to reduce the long term side-effects (late effects) of blood and marrow transplant and we are widely recognized for our investigations into improved methods for collecting peripheral blood cells prior to an autologous transplant. Additionally, we are one of the few blood and marrow transplant centers dedicated to the study of psychosocial aspects of BMT.
Our research project results are presented at national meetings, and we publish them in peer-reviewed journals. We are very proud of the number of our abstracts accepted for presentation at the American Society of Hematology Annual Meeting, the pre-eminent scientific meeting for blood and marrow transplants. At this meeting, investigators from our Program share valuable data to researchers and clinicians from all over the world.
We are actively involved in the Center for International Blood and Marrow Transplant Research. We submit our treatment results to the CIBMTR where it is collated with results from other centers and presented to guide clinical decisions and improve blood and marrow transplant outcomes.